Market Performance Snapshot
Alx Oncology (ALXO) slipped -7.26 % over a 24‑hour window that closed at 03:46 PM Central Europe on Thursday, 22 November 2026. The stock is trading at $1.16 on major exchanges, with a current supply of 138.3 million shares. Its market capitalisation stands at $171.5 million, and only $1.1 million of its shares have changed hands in the past day.
Since the close of the previous month, the share price has declined -28.13 %, underscoring a prolonged downtrend. The 200‑day simple moving average sits at $1.83, well above the current trading level, indicating that the stock is still trading below its recent medium‑term trend. The all‑time high for the past 52 weeks was $2.66 (recorded on 19 February 2026), while the 52‑week low was $0.86 (10 October 2026).
Comparative Peer Activity
| Stock | 24‑hr Performance | Current Price | Market Cap (USD M) | Notes |
|---|---|---|---|---|
| Willow Lane Acquisition (WLII) | 0 % | $10.19 | 205.3 | Flat performance |
| Citizens Community I (CZWI) | -0.47 % | $21.13 | 203.9 | P/E 16.12 |
| Glass House Brands (GLAS) | -0.43 % | $2.28 | 205.0 | Slight decline |
| K2 Capital Acquisition (KTWO) | +0.05 % | $10.11 | 202.4 | Minor rally |
| Rxsight (RXST) | +0.41 % | $4.93 | 203.8 | Upcoming Q3 2026 results |
Rxsight’s forthcoming third‑quarter financials, to be released after market close on November 3 – with a management discussion to follow on a conference call – are expected to provide further context on its Light Adjustable Lens platform. The announcement aligns with the company’s routine reporting cadence and does not yet signal a shift in performance trends.
Strategic Outlook for Alx Oncology
Alx Oncology Holdings Inc. remains a clinical‑stage immuno‑oncology firm headquartered in Burlingame, California. Its therapeutic pipeline focuses on harnessing both innate and adaptive immunity to treat cancer, positioning it within a high‑growth niche of oncology therapeutics. Despite the current valuation compression, the company’s long‑term prospects hinge on the success of its lead candidates and the broader market acceptance of immune‑based oncology treatments.
Market participants should monitor:
- Pipeline Milestones – Upcoming clinical data from ongoing trials could materially influence the share price.
- Regulatory Developments – Any FDA feedback or approvals will be pivotal in shaping investor sentiment.
- Capital Allocation – The company’s ability to secure funding for late‑stage development and commercialization will be a key determinant of long‑term viability.
While the stock’s recent performance reflects short‑term market volatility, Alx Oncology’s foundational strategy and therapeutic focus suggest a resilient long‑term trajectory. Investors should consider both the immediate price dynamics and the company’s strategic roadmap when assessing its future potential.
